Hot Topics Prostate Cancer

Multivitamin use may reduce prostate Ca recurrenceLong-term use of a multivitamin may protect against recurrence of prostate cancer, particularly in those men who have had radical prostatectomy.
PCa Tx delays development of non-metastatic disease in some patientsEnzalutamide (XTANDI) with androgen deprivation therapy delays the development of metastatic disease in men with M0 castration-resistant prostate cancer compared with ADT alone, according to results from the randomized phase III PROSPER study.
Newer agent efficacious in non-metastatic castration-resistant PCaAdding apalutamide prior to metastases may benefit men with prostate cancer who are no longer responding to androgen deprivation therapy, according to new phase III study findings.
Chemo improves QoL in men with non-metastatic, metastatic PCaDocetaxel (Taxotere) appears to help improve overall quality of life and delay time for subsequent therapy in men with both non-metastatic and metastatic prostate cancer, according to a new analysis of STAMPEDE trial results.
ADT+EBRT improves OS in men with post-RP LN metastases"While improving local control seems to be important, especially in those with high-risk features, it’s not clear whether adjuvant EBRT is necessarily better than early salvage EBRT," writes Badar M. Mian, MD.
Is favorable-risk GG2 prostate Ca suitable for active surveillance?"The management of prostate cancer always requires caution to safeguard against avoidable risks from both the treatment and the monitoring protocol," writes Badar M. Mian, MD.
Genetic testing for prostate Ca: What the experts sayA recently published statement provides an evidence-based, consensus-driven framework on the role of genetic testing for determining prostate cancer risk, screening, and management.
Liquid biopsy tests for prostate Ca show low congruenceThe findings “[raise] the specter that patients could potentially receive different treatments depending on the cell-free DNA platform,” authors of a recent research letter write.
Biennial vs. annual prostate biopsies: What the data showAmong men undergoing active surveillance for low-risk prostate cancer, biennial biopsies appear to be an acceptable alternative to annual biopsies.
Prostate Ca test linked to reduction in biopsiesPatients with non-suspicious digital rectal exam findings and total PSA in the 4.0- to 10.0-ng/mL range are far less likely to be biopsied if they’ve undergone Prostate Health Index (phi) testing than if they don’t.